---
title: "AnaptysBio kündigt Abspaltung von Biopharma-Geschäft und Royalty-Vermögenswerten bis Ende 2026 an"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275031151.md"
datetime: "2026-02-05T21:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275031151.md)
  - [en](https://longbridge.com/en/news/275031151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275031151.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275031151.md) | [English](https://longbridge.com/en/news/275031151.md)


# AnaptysBio kündigt Abspaltung von Biopharma-Geschäft und Royalty-Vermögenswerten bis Ende 2026 an

AnaptysBio Inc. hat angekündigt, bis Ende 2026 seine Biopharma-Aktivitäten von den umfangreichen Lizenzgebühren-Vermögenswerten zu trennen. Ziel dieser Unternehmensumstrukturierung ist es, Investoren die Möglichkeit zu geben, ihre Anlagestrategien gezielter auf die jeweiligen Geschäftsfelder und finanziellen Ziele auszurichten. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649775-en) on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Anaptysbio (ANAB.US)](https://longbridge.com/zh-HK/quote/ANAB.US.md)

## 相關資訊與研究

- [What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings?](https://longbridge.com/zh-HK/news/278095134.md)
- [Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted](https://longbridge.com/zh-HK/news/277898930.md)
- [S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities](https://longbridge.com/zh-HK/news/278899470.md)
- [BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards](https://longbridge.com/zh-HK/news/279051346.md)
- [IDBS Wins Best Biologics Digitalisation: Software Innovation Award, at the 2026 Asia Pacific Biopharma Excellence Awards](https://longbridge.com/zh-HK/news/278909817.md)